A business in context

RNTX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-09-04 · 0001193125-26-383726 · Items 7.01,9.01

  2. 8-K · Current report

    Report date 2026-08-21 · 0001193125-26-371260 · Items 3.01

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-350270

  4. 8-K · Current report

    Report date 2026-07-20 · 0001193125-26-310315 · Items 5.07

  5. DEF 14A · Proxy statement

    Report date 2026-07-20 · 0001193125-26-260809

  6. 4 · Ownership change

    Report date 2026-05-21 · 0001193125-26-245832

  7. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-225352

  8. 4 · Ownership change

    Report date 2026-04-30 · 0001193125-26-220718

  9. 8-K · Current report

    Report date 2026-04-30 · 0001193125-26-204006 · Items 1.01,8.01,9.01

  10. 10-K/A · Annual report

    Report date 2025-12-31 · 0001193125-26-178787

  11. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-126385

  12. 8-K · Current report

    Report date 2026-02-24 · 0001193125-26-084012 · Items 1.01,2.03,3.02,9.01

  13. 8-K · Current report

    Report date 2026-02-16 · 0001193125-26-059545 · Items 5.02

  14. 8-K · Current report

    Report date 2026-01-15 · 0001193125-26-015524 · Items 1.01,2.03,3.02,9.01

  15. 8-K · Current report

    Report date 2025-12-11 · 0001193125-25-316225 · Items 1.02

  16. 4 · Ownership change

    Report date 2025-11-14 · 0000921895-25-003156

  17. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-281622

  18. 8-K · Current report

    Report date 2025-11-03 · 0001193125-25-261706 · Items 8.01,9.01

  19. 4 · Ownership change

    Report date 2025-10-24 · 0000921895-25-002819

  20. 8-K · Current report

    Report date 2025-10-23 · 0001193125-25-250175 · Items 1.01,2.03,3.02,9.01

  21. 8-K · Current report

    Report date 2025-10-09 · 0001193125-25-235152 · Items 8.01,9.01

  22. 8-K · Current report

    Report date 2025-09-16 · 0001193125-25-210050 · Items 8.01

  23. 8-K · Current report

    Report date 2025-09-08 · 0001193125-25-198816 · Items 1.01,2.03,3.02,9.01

  24. 8-K · Current report

    Report date 2025-08-19 · 0001193125-25-183073 · Items 8.01,9.01

  25. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-108836

  26. 8-K · Current report

    Report date 2025-07-29 · 0001193125-25-168830 · Items 1.01,2.03,3.02,9.01

  27. 8-K · Current report

    Report date 2025-07-23 · 0001193125-25-163400 · Items 5.07

  28. 4 · Ownership change

    Report date 2025-07-23 · 0000950170-25-098046

  29. 4 · Ownership change

    Report date 2025-07-23 · 0000950170-25-098044

  30. 4 · Ownership change

    Report date 2025-07-23 · 0000950170-25-098043

  31. 4 · Ownership change

    Report date 2025-07-23 · 0000950170-25-098041

  32. 8-K · Current report

    Report date 2025-07-08 · 0001193125-25-158192 · Items 5.03,8.01,9.01

  33. 8-K · Current report

    Report date 2025-06-24 · 0001193125-25-145711 · Items 8.01

  34. 8-K · Current report

    Report date 2025-06-10 · 0001193125-25-139950 · Items 8.01

  35. 8-K · Current report

    Report date 2025-05-15 · 0001193125-25-120824 · Items 2.02,9.01

  36. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-072607

  37. DEF 14A · Proxy statement

    Report date 2025-06-24 · 0001193125-25-117820

  38. 10-K/A · Annual report

    Report date 2024-12-31 · 0001193125-25-107666

  39. 8-K · Current report

    Report date 2025-04-21 · 0001193125-25-087955 · Items 1.01,3.02,9.01

  40. 8-K · Current report

    Report date 2025-04-16 · 0001193125-25-084340 · Items 4.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 5 transaction rows5PSale: 0 transaction rows0SGrant / award: 1 transaction rows1AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

6 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-05-27
2026-05-28
VON RICKENBACH JOSEF HP · Purchase
Acquired
Common stock , $0.001 par value4500.01.07
2026-05-26
2026-05-28
VON RICKENBACH JOSEF HP · Purchase
Acquired
Common stock , $0.001 par value23190.01.06
2026-05-22
2026-05-28
VON RICKENBACH JOSEF HP · Purchase
Acquired
Common stock , $0.001 par value15950.01.05
2026-05-21
2026-05-28
VON RICKENBACH JOSEF HP · Purchase
Acquired
Common stock , $0.001 par value3420.01.04
2026-05-08
2026-05-13
WINDSOR JAMES BRIANA · Grant / award
Disposed
Stock Option (Right to Buy)
Derivative security
150000.00.0
2026-04-30
2026-05-13
WINDSOR JAMES BRIANP · Purchase
Acquired
Common stock , $0.001 par value25000.01.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001420565Rein Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names
  • Aileron Therapeutics, Inc. · former SEC name · 2024-04-01 to 2024-12-09
  • AILERON THERAPEUTICS INC · former SEC name · 2007-12-03 to 2024-03-29

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$0$0
2023-12-31$0$0
2022-12-31$0$0
2021-12-31$0$0
2020-12-31$0$0
2019-12-31$0$0
2018-12-31$0$0
2017-12-31$0$0

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗